INmune Bio Enters Warrant Exercise and Extension Agreement

What Happened
INmune Bio, Inc. announced on June 30, 2026 that it entered into a warrant inducement letter and an amendment with certain holders of its April 2024 common stock purchase warrants. Under the inducement, holders agreed to exercise 50% of those warrants — 647,112 warrants — for cash at a reduced exercise price of $1.40 per share (down from $1.95). The company expects to receive aggregate proceeds of $905,957 from these exercises. The amendment extends the maturity date for the remaining 50% of those warrants from June 30, 2026 to December 31, 2027. The shares underlying the warrants are registrable under an effective registration statement (File No. 333-279036).

Key Details

• 647,112 warrants will be exercised for cash at a reduced price of $1.40 per share.
• Aggregate expected proceeds: $905,957.
• Remaining 50% of the April 2024 warrants amended: maturity extended from June 30, 2026 to December 31, 2027.
• Warrants were originally issued April 24 & 29, 2024 and previously amended on December 22, 2025; underlying shares are covered by an effective registration statement.

Why It Matters
This transaction provides INmune Bio with near‑term cash (about $906k) while giving warrant holders a lower exercise price and extending the timeline for the remaining warrants. For investors, note both the immediate capital inflow and the potential for additional share dilution: exercised warrants will increase outstanding shares now, and the extended warrants remain a source of possible future dilution through December 2027. The issuance is covered by an effective registration statement, which facilitates issuance or resale of the underlying shares.